A leader from the drug research and development company discusses unique problems faced by COVID-19 patients with prior cancer and autoimmune diagnoses.
The agency has approved the antiviral drug Veklury (remdesivir), produced by Gilead, for hospitalized patients 12 years and over diagnosed with the virus.
The pharmaceutical firm’s More to uS is a UK-centered campaign that shares stories of people living (and thriving) after a multiple sclerosis diagnosis.
The company's Spectus and Percepta platforms offer features to help researchers meet challenges associated with working and collaborating in the pandemic.
eClinical Solutions, a provider of clinical data service solutions, has seen an increase in interest in clinical data platform and other digital products.
A veteran with more than 20 years of experience talks about the vitality of recruiting an inclusive patient population, and the perils of falling short.
As the pandemic maintains its hold, the US agency continues to issue advice and take action related to testing, treatment and information on the virus.
Companies like Biofourmis, THREAD and other virtual tech specialists have seen infusions of funds from investors bullish on decentralized clinical trials.
The survey, unveiled ahead of next week's CPhI Festival of Pharma, reveals perspectives, concerns and future plans of more than 500 industry executives.
The pharma ingredients provider discusses new products, supply-chain obstacles, and what the future of the industry might hold, ahead of the online event.
TeleConsent empowers trial teams to obtain informed consent and re-consent from patients participating in clinical studies, within a fully remote system.
Ena Respiratory’s preventative nasal spray treatment could reach human trials within four months, following results from an animal study released today which showed the spray reduced COVID-19 replication by up to 96%.
The technology combines predictive analytics and commercial services to help pharma firms and partners maximize drug discovery and development efforts.
Thermo Fisher Scientific will partner with AstraZeneca and the University of Nebraska Medical Center to advance biomarker discovery and characterization.
